The mutational status and histopathologic grade of patients with chemorefractory colorectal liver metastases (CRLM) may predict survival after Y90 radioembolization therapy, according to a study published in Oncotarget. | Read More
Using 3D voxel-based dosimetry in patients with hepatocellular carcinoma treated by yttrium-90 resin microspheres radioembolization, a new study determined that complete tumor targeting and 90Y dose to tumor are independent factors associated with clinical outcomes. | Read More
Interventional radiologists who are interested in performing Y90 should be aware of clinical red flags including bilirubin trends, potent radiosensitizers, prior biliary intervention, and the presence of ascites, according to a presentation by Ripal Gandhi, MD, FSVM, FSIR at the Symposium on Clinical Interventional Oncology. | Read More
According to a new study, 90Y transarterial radioembolization around immunotherapy is safe and effective and the combined treatment may improve hepatic progression-free survival and overall survival in patients with hepatic metastases from uveal melanoma. | Read More
In an exploratory case of a patient with metastatic colorectal cancer, a hotspot panel of cancer-associated gene mutations was used to identify tumor-specific mutations. | Read More

Spotlight

Interventional radiologists who are interested in performing Y90 should be aware of clinical red flags including bilirubin trends, potent radiosensitizers, prior biliary intervention, and the presence of ascites, according to a presentation by Ripal Gandhi, MD, FSVM, FSIR at the Symposium on Clinical Interventional Oncology.
In this video, Alice Gillams, MB, CHB, discusses the benefits of liver directed therapy.
Interventional radiologists who are interested in performing adrenal ablations would benefit from reviewing the literature and including both an endocrinologist and anesthesiologist on the treatment team, according to a presentation by Debra Gervais, MD.